nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—BCL2—Apoptosis Modulation and Signaling—BAG3—dilated cardiomyopathy	0.0262	0.0867	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—ZBTB17—dilated cardiomyopathy	0.0162	0.0534	CbGpPWpGaD
Rasagiline—Anuria—Lisinopril—dilated cardiomyopathy	0.014	0.0201	CcSEcCtD
Rasagiline—Atrioventricular block complete—Lisinopril—dilated cardiomyopathy	0.014	0.0201	CcSEcCtD
Rasagiline—Amenorrhoea—Spironolactone—dilated cardiomyopathy	0.0137	0.0196	CcSEcCtD
Rasagiline—Flank pain—Lisinopril—dilated cardiomyopathy	0.0122	0.0175	CcSEcCtD
Rasagiline—Dysaesthesia—Lisinopril—dilated cardiomyopathy	0.0113	0.0163	CcSEcCtD
Rasagiline—Cramps of lower extremities—Spironolactone—dilated cardiomyopathy	0.011	0.0158	CcSEcCtD
Rasagiline—Gynaecomastia—Spironolactone—dilated cardiomyopathy	0.0107	0.0154	CcSEcCtD
Rasagiline—Bursitis—Lisinopril—dilated cardiomyopathy	0.0101	0.0145	CcSEcCtD
Rasagiline—Cerebral ischaemia—Lisinopril—dilated cardiomyopathy	0.0101	0.0145	CcSEcCtD
Rasagiline—Renal failure acute—Spironolactone—dilated cardiomyopathy	0.00944	0.0135	CcSEcCtD
Rasagiline—Apathy—Furosemide—dilated cardiomyopathy	0.00915	0.0131	CcSEcCtD
Rasagiline—Flat affect—Furosemide—dilated cardiomyopathy	0.00907	0.013	CcSEcCtD
Rasagiline—BCL2—Apoptosis—DSG2—dilated cardiomyopathy	0.009	0.0297	CbGpPWpGaD
Rasagiline—Blindness—Lisinopril—dilated cardiomyopathy	0.00886	0.0127	CcSEcCtD
Rasagiline—BCL2—FAS pathway and Stress induction of HSP regulation—LMNA—dilated cardiomyopathy	0.0088	0.0291	CbGpPWpGaD
Rasagiline—Ataxia—Spironolactone—dilated cardiomyopathy	0.0082	0.0118	CcSEcCtD
Rasagiline—BCL2—RXR and RAR heterodimerization with other nuclear receptor—RPS6KB1—dilated cardiomyopathy	0.00819	0.0271	CbGpPWpGaD
Rasagiline—Nephrolithiasis—Furosemide—dilated cardiomyopathy	0.00813	0.0117	CcSEcCtD
Rasagiline—Laryngeal oedema—Lisinopril—dilated cardiomyopathy	0.00764	0.011	CcSEcCtD
Rasagiline—Hypocalcaemia—Furosemide—dilated cardiomyopathy	0.00714	0.0102	CcSEcCtD
Rasagiline—Drug interaction—Furosemide—dilated cardiomyopathy	0.00704	0.0101	CcSEcCtD
Rasagiline—BCL2—IL2 signaling events mediated by STAT5—FASLG—dilated cardiomyopathy	0.00698	0.0231	CbGpPWpGaD
Rasagiline—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00694	0.00995	CcSEcCtD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—LMNA—dilated cardiomyopathy	0.00689	0.0228	CbGpPWpGaD
Rasagiline—BCL2—HIV-1 Nef: Negative effector of Fas and TNF-alpha—FASLG—dilated cardiomyopathy	0.00647	0.0214	CbGpPWpGaD
Rasagiline—Ventricular fibrillation—Lisinopril—dilated cardiomyopathy	0.0064	0.00918	CcSEcCtD
Rasagiline—Pleural effusion—Lisinopril—dilated cardiomyopathy	0.0064	0.00918	CcSEcCtD
Rasagiline—BCL2—HIV-1 Nef: Negative effector of Fas and TNF-alpha—FAS—dilated cardiomyopathy	0.00624	0.0206	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—RPS6KB1—dilated cardiomyopathy	0.00618	0.0204	CbGpPWpGaD
Rasagiline—Cramps of lower extremities—Furosemide—dilated cardiomyopathy	0.006	0.00861	CcSEcCtD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—GPX1—dilated cardiomyopathy	0.00595	0.0197	CbGpPWpGaD
Rasagiline—Urine output increased—Furosemide—dilated cardiomyopathy	0.00591	0.00847	CcSEcCtD
Rasagiline—BCL2—IL-5 Signaling Pathway—RPS6KB1—dilated cardiomyopathy	0.0058	0.0192	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—LAMA4—dilated cardiomyopathy	0.0058	0.0192	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—RPS6KB1—dilated cardiomyopathy	0.00558	0.0184	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—RAC1—dilated cardiomyopathy	0.00558	0.0184	CbGpPWpGaD
Rasagiline—Accidental injury—Lisinopril—dilated cardiomyopathy	0.00554	0.00794	CcSEcCtD
Rasagiline—Thrombophlebitis—Furosemide—dilated cardiomyopathy	0.00548	0.00786	CcSEcCtD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—RAC1—dilated cardiomyopathy	0.00546	0.0181	CbGpPWpGaD
Rasagiline—Ventricular extrasystoles—Lisinopril—dilated cardiomyopathy	0.00543	0.00778	CcSEcCtD
Rasagiline—Polyuria—Furosemide—dilated cardiomyopathy	0.0054	0.00774	CcSEcCtD
Rasagiline—BCL2—Apoptosis—DSP—dilated cardiomyopathy	0.00539	0.0178	CbGpPWpGaD
Rasagiline—Arthropathy—Lisinopril—dilated cardiomyopathy	0.00539	0.00773	CcSEcCtD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—RPS6KB1—dilated cardiomyopathy	0.00538	0.0178	CbGpPWpGaD
Rasagiline—Cough increased—Lisinopril—dilated cardiomyopathy	0.00536	0.00768	CcSEcCtD
Rasagiline—BCL2—FAS pathway and Stress induction of HSP regulation—FASLG—dilated cardiomyopathy	0.00533	0.0176	CbGpPWpGaD
Rasagiline—Alopecia—Spironolactone—dilated cardiomyopathy	0.00533	0.00764	CcSEcCtD
Rasagiline—Deafness—Furosemide—dilated cardiomyopathy	0.0053	0.0076	CcSEcCtD
Rasagiline—Vascular purpura—Furosemide—dilated cardiomyopathy	0.0053	0.0076	CcSEcCtD
Rasagiline—Drug interaction—Lisinopril—dilated cardiomyopathy	0.00528	0.00758	CcSEcCtD
Rasagiline—BCL2—FAS pathway and Stress induction of HSP regulation—FAS—dilated cardiomyopathy	0.00514	0.017	CbGpPWpGaD
Rasagiline—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00505	0.00724	CcSEcCtD
Rasagiline—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.00503	0.00721	CcSEcCtD
Rasagiline—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.00496	0.00712	CcSEcCtD
Rasagiline—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00496	0.00711	CcSEcCtD
Rasagiline—Neck pain—Lisinopril—dilated cardiomyopathy	0.00496	0.00711	CcSEcCtD
Rasagiline—Purpura—Furosemide—dilated cardiomyopathy	0.00492	0.00706	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00491	0.0162	CbGpPWpGaD
Rasagiline—Ventricular tachycardia—Lisinopril—dilated cardiomyopathy	0.0049	0.00703	CcSEcCtD
Rasagiline—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00487	0.00698	CcSEcCtD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—RPS6KB1—dilated cardiomyopathy	0.00478	0.0158	CbGpPWpGaD
Rasagiline—Malaise—Spironolactone—dilated cardiomyopathy	0.00473	0.00679	CcSEcCtD
Rasagiline—Leukopenia—Spironolactone—dilated cardiomyopathy	0.0047	0.00674	CcSEcCtD
Rasagiline—Neuropathy—Lisinopril—dilated cardiomyopathy	0.0046	0.0066	CcSEcCtD
Rasagiline—Photophobia—Lisinopril—dilated cardiomyopathy	0.0046	0.0066	CcSEcCtD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—ITGB1—dilated cardiomyopathy	0.00453	0.015	CbGpPWpGaD
Rasagiline—Urinary retention—Furosemide—dilated cardiomyopathy	0.00451	0.00647	CcSEcCtD
Rasagiline—Discomfort—Spironolactone—dilated cardiomyopathy	0.00442	0.00633	CcSEcCtD
Rasagiline—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00433	0.00621	CcSEcCtD
Rasagiline—Confusional state—Spironolactone—dilated cardiomyopathy	0.00432	0.00619	CcSEcCtD
Rasagiline—Hypertonia—Lisinopril—dilated cardiomyopathy	0.0043	0.00616	CcSEcCtD
Rasagiline—BCL2—Kit receptor signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00425	0.0141	CbGpPWpGaD
Rasagiline—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00418	0.006	CcSEcCtD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—FASLG—dilated cardiomyopathy	0.00418	0.0138	CbGpPWpGaD
Rasagiline—BCL2—Overview of nanoparticle effects—TNF—dilated cardiomyopathy	0.00412	0.0136	CbGpPWpGaD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—FAS—dilated cardiomyopathy	0.00403	0.0133	CbGpPWpGaD
Rasagiline—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00402	0.00576	CcSEcCtD
Rasagiline—Eczema—Lisinopril—dilated cardiomyopathy	0.00396	0.00568	CcSEcCtD
Rasagiline—Injury—Lisinopril—dilated cardiomyopathy	0.00387	0.00555	CcSEcCtD
Rasagiline—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.00385	0.00553	CcSEcCtD
Rasagiline—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00384	0.0055	CcSEcCtD
Rasagiline—Somnolence—Spironolactone—dilated cardiomyopathy	0.00381	0.00546	CcSEcCtD
Rasagiline—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00379	0.00543	CcSEcCtD
Rasagiline—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00374	0.00537	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—VCL—dilated cardiomyopathy	0.00373	0.0123	CbGpPWpGaD
Rasagiline—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.0037	0.0053	CcSEcCtD
Rasagiline—Arthritis—Lisinopril—dilated cardiomyopathy	0.00366	0.00525	CcSEcCtD
Rasagiline—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00363	0.00521	CcSEcCtD
Rasagiline—Diplopia—Lisinopril—dilated cardiomyopathy	0.00356	0.0051	CcSEcCtD
Rasagiline—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00356	0.0051	CcSEcCtD
Rasagiline—BCL2—Corticotropin-releasing hormone—GJA1—dilated cardiomyopathy	0.00353	0.0117	CbGpPWpGaD
Rasagiline—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00353	0.00506	CcSEcCtD
Rasagiline—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00353	0.00506	CcSEcCtD
Rasagiline—Sweating—Furosemide—dilated cardiomyopathy	0.0035	0.00502	CcSEcCtD
Rasagiline—BCL2—IL-5 Signaling Pathway—RAF1—dilated cardiomyopathy	0.00348	0.0115	CbGpPWpGaD
Rasagiline—Face oedema—Lisinopril—dilated cardiomyopathy	0.00344	0.00493	CcSEcCtD
Rasagiline—Urticaria—Spironolactone—dilated cardiomyopathy	0.0034	0.00488	CcSEcCtD
Rasagiline—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00339	0.00486	CcSEcCtD
Rasagiline—Ataxia—Lisinopril—dilated cardiomyopathy	0.00335	0.0048	CcSEcCtD
Rasagiline—BCL2—IL-2 Signaling Pathway—RAF1—dilated cardiomyopathy	0.00334	0.011	CbGpPWpGaD
Rasagiline—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00325	0.00466	CcSEcCtD
Rasagiline—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00324	0.00465	CcSEcCtD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—RAF1—dilated cardiomyopathy	0.00322	0.0106	CbGpPWpGaD
Rasagiline—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00322	0.00461	CcSEcCtD
Rasagiline—BCL2—RXR and RAR heterodimerization with other nuclear receptor—TNF—dilated cardiomyopathy	0.0032	0.0106	CbGpPWpGaD
Rasagiline—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00316	0.00453	CcSEcCtD
Rasagiline—BCL2—Apoptosis—LMNA—dilated cardiomyopathy	0.0031	0.0102	CbGpPWpGaD
Rasagiline—Asthma—Lisinopril—dilated cardiomyopathy	0.00308	0.00441	CcSEcCtD
Rasagiline—Influenza—Lisinopril—dilated cardiomyopathy	0.00308	0.00441	CcSEcCtD
Rasagiline—Eye disorder—Furosemide—dilated cardiomyopathy	0.00307	0.0044	CcSEcCtD
Rasagiline—BCL2—Apoptosis—FASLG—dilated cardiomyopathy	0.00306	0.0101	CbGpPWpGaD
Rasagiline—Pruritus—Spironolactone—dilated cardiomyopathy	0.00303	0.00435	CcSEcCtD
Rasagiline—BCL2—Ceramide signaling pathway—RAF1—dilated cardiomyopathy	0.003	0.00993	CbGpPWpGaD
Rasagiline—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.003	0.0043	CcSEcCtD
Rasagiline—Angiopathy—Furosemide—dilated cardiomyopathy	0.00298	0.00427	CcSEcCtD
Rasagiline—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00296	0.00425	CcSEcCtD
Rasagiline—BCL2—IL-3 Signaling Pathway—RAF1—dilated cardiomyopathy	0.00295	0.00977	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—FAS—dilated cardiomyopathy	0.00295	0.00976	CbGpPWpGaD
Rasagiline—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00293	0.0042	CcSEcCtD
Rasagiline—Dysuria—Lisinopril—dilated cardiomyopathy	0.00288	0.00412	CcSEcCtD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—FASLG—dilated cardiomyopathy	0.00287	0.0095	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—RAF1—dilated cardiomyopathy	0.00286	0.00946	CbGpPWpGaD
Rasagiline—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00286	0.0041	CcSEcCtD
Rasagiline—Malnutrition—Furosemide—dilated cardiomyopathy	0.00286	0.0041	CcSEcCtD
Rasagiline—Dizziness—Spironolactone—dilated cardiomyopathy	0.00283	0.00406	CcSEcCtD
Rasagiline—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00283	0.00406	CcSEcCtD
Rasagiline—Flatulence—Furosemide—dilated cardiomyopathy	0.00281	0.00404	CcSEcCtD
Rasagiline—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00281	0.00403	CcSEcCtD
Rasagiline—Dysgeusia—Furosemide—dilated cardiomyopathy	0.0028	0.00401	CcSEcCtD
Rasagiline—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00278	0.00399	CcSEcCtD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—FAS—dilated cardiomyopathy	0.00277	0.00916	CbGpPWpGaD
Rasagiline—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00275	0.00394	CcSEcCtD
Rasagiline—Depression—Lisinopril—dilated cardiomyopathy	0.00273	0.00392	CcSEcCtD
Rasagiline—BCL2—IL2-mediated signaling events—RAF1—dilated cardiomyopathy	0.00273	0.00904	CbGpPWpGaD
Rasagiline—Vomiting—Spironolactone—dilated cardiomyopathy	0.00272	0.00391	CcSEcCtD
Rasagiline—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.0027	0.00388	CcSEcCtD
Rasagiline—Rash—Spironolactone—dilated cardiomyopathy	0.0027	0.00387	CcSEcCtD
Rasagiline—Dermatitis—Spironolactone—dilated cardiomyopathy	0.0027	0.00387	CcSEcCtD
Rasagiline—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00269	0.00385	CcSEcCtD
Rasagiline—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00269	0.00385	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—SOD2—dilated cardiomyopathy	0.00268	0.00887	CbGpPWpGaD
Rasagiline—Headache—Spironolactone—dilated cardiomyopathy	0.00268	0.00385	CcSEcCtD
Rasagiline—Jaundice—Lisinopril—dilated cardiomyopathy	0.00267	0.00383	CcSEcCtD
Rasagiline—BCL2—HIV-1 Nef: Negative effector of Fas and TNF-alpha—TNF—dilated cardiomyopathy	0.00265	0.00875	CbGpPWpGaD
Rasagiline—Anaemia—Furosemide—dilated cardiomyopathy	0.00264	0.00379	CcSEcCtD
Rasagiline—Sweating—Lisinopril—dilated cardiomyopathy	0.00263	0.00377	CcSEcCtD
Rasagiline—Agitation—Furosemide—dilated cardiomyopathy	0.00262	0.00376	CcSEcCtD
Rasagiline—Haematuria—Lisinopril—dilated cardiomyopathy	0.00261	0.00375	CcSEcCtD
Rasagiline—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00259	0.00371	CcSEcCtD
Rasagiline—CYP1A2—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.00257	0.00849	CbGpPWpGaD
Rasagiline—Vertigo—Furosemide—dilated cardiomyopathy	0.00257	0.00368	CcSEcCtD
Rasagiline—Leukopenia—Furosemide—dilated cardiomyopathy	0.00256	0.00367	CcSEcCtD
Rasagiline—BCL2—Kit receptor signaling pathway—RAF1—dilated cardiomyopathy	0.00255	0.00842	CbGpPWpGaD
Rasagiline—Nausea—Spironolactone—dilated cardiomyopathy	0.00255	0.00365	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—FASLG—dilated cardiomyopathy	0.00249	0.00822	CbGpPWpGaD
Rasagiline—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00247	0.00354	CcSEcCtD
Rasagiline—Hallucination—Lisinopril—dilated cardiomyopathy	0.00245	0.00351	CcSEcCtD
Rasagiline—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00243	0.00349	CcSEcCtD
Rasagiline—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00243	0.00348	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00242	0.00346	CcSEcCtD
Rasagiline—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00241	0.00346	CcSEcCtD
Rasagiline—Dry mouth—Furosemide—dilated cardiomyopathy	0.00238	0.00341	CcSEcCtD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—TNF—dilated cardiomyopathy	0.00236	0.00782	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—RAC1—dilated cardiomyopathy	0.00235	0.00777	CbGpPWpGaD
Rasagiline—Confusional state—Furosemide—dilated cardiomyopathy	0.00235	0.00337	CcSEcCtD
Rasagiline—Shock—Furosemide—dilated cardiomyopathy	0.00229	0.00329	CcSEcCtD
Rasagiline—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00229	0.00328	CcSEcCtD
Rasagiline—Skin disorder—Furosemide—dilated cardiomyopathy	0.00226	0.00325	CcSEcCtD
Rasagiline—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00225	0.00323	CcSEcCtD
Rasagiline—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00223	0.0032	CcSEcCtD
Rasagiline—Anorexia—Furosemide—dilated cardiomyopathy	0.00222	0.00319	CcSEcCtD
Rasagiline—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00222	0.00318	CcSEcCtD
Rasagiline—Chills—Lisinopril—dilated cardiomyopathy	0.00221	0.00317	CcSEcCtD
Rasagiline—BCL2—FAS pathway and Stress induction of HSP regulation—TNF—dilated cardiomyopathy	0.00218	0.00722	CbGpPWpGaD
Rasagiline—Hypotension—Furosemide—dilated cardiomyopathy	0.00218	0.00312	CcSEcCtD
Rasagiline—Alopecia—Lisinopril—dilated cardiomyopathy	0.00218	0.00312	CcSEcCtD
Rasagiline—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00216	0.00309	CcSEcCtD
Rasagiline—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00214	0.00307	CcSEcCtD
Rasagiline—Flatulence—Lisinopril—dilated cardiomyopathy	0.00211	0.00303	CcSEcCtD
Rasagiline—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.0021	0.00301	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—GPX1—dilated cardiomyopathy	0.0021	0.00693	CbGpPWpGaD
Rasagiline—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00209	0.003	CcSEcCtD
Rasagiline—Back pain—Lisinopril—dilated cardiomyopathy	0.00207	0.00297	CcSEcCtD
Rasagiline—Somnolence—Furosemide—dilated cardiomyopathy	0.00207	0.00297	CcSEcCtD
Rasagiline—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00206	0.00295	CcSEcCtD
Rasagiline—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00203	0.00291	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00201	0.00289	CcSEcCtD
Rasagiline—Tremor—Lisinopril—dilated cardiomyopathy	0.00201	0.00288	CcSEcCtD
Rasagiline—Constipation—Furosemide—dilated cardiomyopathy	0.00199	0.00286	CcSEcCtD
Rasagiline—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00199	0.00285	CcSEcCtD
Rasagiline—Anaemia—Lisinopril—dilated cardiomyopathy	0.00198	0.00284	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—FAS—dilated cardiomyopathy	0.00196	0.00649	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—TNF—dilated cardiomyopathy	0.00196	0.00648	CbGpPWpGaD
Rasagiline—Malaise—Lisinopril—dilated cardiomyopathy	0.00193	0.00277	CcSEcCtD
Rasagiline—Vertigo—Lisinopril—dilated cardiomyopathy	0.00193	0.00276	CcSEcCtD
Rasagiline—Syncope—Lisinopril—dilated cardiomyopathy	0.00192	0.00276	CcSEcCtD
Rasagiline—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00192	0.00275	CcSEcCtD
Rasagiline—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00192	0.00275	CcSEcCtD
Rasagiline—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00191	0.00273	CcSEcCtD
Rasagiline—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00188	0.0027	CcSEcCtD
Rasagiline—BCL2—Apoptosis—FASLG—dilated cardiomyopathy	0.00188	0.0062	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—ITGB1—dilated cardiomyopathy	0.00187	0.0062	CbGpPWpGaD
Rasagiline—Cough—Lisinopril—dilated cardiomyopathy	0.00187	0.00268	CcSEcCtD
Rasagiline—Urticaria—Furosemide—dilated cardiomyopathy	0.00185	0.00266	CcSEcCtD
Rasagiline—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00184	0.00264	CcSEcCtD
Rasagiline—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00184	0.00264	CcSEcCtD
Rasagiline—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00182	0.00262	CcSEcCtD
Rasagiline—Chest pain—Lisinopril—dilated cardiomyopathy	0.00182	0.00262	CcSEcCtD
Rasagiline—Anxiety—Lisinopril—dilated cardiomyopathy	0.00182	0.00261	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00181	0.0026	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	0.00181	0.00599	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—FAS—dilated cardiomyopathy	0.00181	0.00598	CbGpPWpGaD
Rasagiline—Discomfort—Lisinopril—dilated cardiomyopathy	0.0018	0.00258	CcSEcCtD
Rasagiline—BCL2—Corticotropin-releasing hormone—RAF1—dilated cardiomyopathy	0.00179	0.0059	CbGpPWpGaD
Rasagiline—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00178	0.00256	CcSEcCtD
Rasagiline—Confusional state—Lisinopril—dilated cardiomyopathy	0.00176	0.00253	CcSEcCtD
Rasagiline—Infection—Lisinopril—dilated cardiomyopathy	0.00174	0.00249	CcSEcCtD
Rasagiline—Shock—Lisinopril—dilated cardiomyopathy	0.00172	0.00247	CcSEcCtD
Rasagiline—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00172	0.00246	CcSEcCtD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—TNF—dilated cardiomyopathy	0.00171	0.00565	CbGpPWpGaD
Rasagiline—Skin disorder—Lisinopril—dilated cardiomyopathy	0.0017	0.00244	CcSEcCtD
Rasagiline—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00169	0.00242	CcSEcCtD
Rasagiline—Asthenia—Furosemide—dilated cardiomyopathy	0.00167	0.0024	CcSEcCtD
Rasagiline—Anorexia—Lisinopril—dilated cardiomyopathy	0.00167	0.00239	CcSEcCtD
Rasagiline—Pruritus—Furosemide—dilated cardiomyopathy	0.00165	0.00236	CcSEcCtD
Rasagiline—Hypotension—Lisinopril—dilated cardiomyopathy	0.00163	0.00234	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—RAF1—dilated cardiomyopathy	0.00161	0.00531	CbGpPWpGaD
Rasagiline—Diarrhoea—Furosemide—dilated cardiomyopathy	0.0016	0.00229	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00159	0.00228	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.00159	0.00525	CbGpPWpGaD
Rasagiline—Insomnia—Lisinopril—dilated cardiomyopathy	0.00158	0.00227	CcSEcCtD
Rasagiline—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00157	0.00225	CcSEcCtD
Rasagiline—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00156	0.00224	CcSEcCtD
Rasagiline—Somnolence—Lisinopril—dilated cardiomyopathy	0.00155	0.00223	CcSEcCtD
Rasagiline—Dizziness—Furosemide—dilated cardiomyopathy	0.00154	0.00221	CcSEcCtD
Rasagiline—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00154	0.00221	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.00153	0.00506	CbGpPWpGaD
Rasagiline—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00152	0.00218	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00151	0.00217	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—RAC1—dilated cardiomyopathy	0.00151	0.00498	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.0015	0.00496	CbGpPWpGaD
Rasagiline—Constipation—Lisinopril—dilated cardiomyopathy	0.0015	0.00214	CcSEcCtD
Rasagiline—Vomiting—Furosemide—dilated cardiomyopathy	0.00148	0.00213	CcSEcCtD
Rasagiline—Rash—Furosemide—dilated cardiomyopathy	0.00147	0.00211	CcSEcCtD
Rasagiline—Dermatitis—Furosemide—dilated cardiomyopathy	0.00147	0.00211	CcSEcCtD
Rasagiline—Headache—Furosemide—dilated cardiomyopathy	0.00146	0.00209	CcSEcCtD
Rasagiline—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00144	0.00207	CcSEcCtD
Rasagiline—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00143	0.00205	CcSEcCtD
Rasagiline—Urticaria—Lisinopril—dilated cardiomyopathy	0.00139	0.00199	CcSEcCtD
Rasagiline—Nausea—Furosemide—dilated cardiomyopathy	0.00138	0.00199	CcSEcCtD
Rasagiline—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00138	0.00198	CcSEcCtD
Rasagiline—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00138	0.00198	CcSEcCtD
Rasagiline—MAOB—Metabolism—ANKRD1—dilated cardiomyopathy	0.00136	0.00448	CbGpPWpGaD
Rasagiline—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00129	0.00185	CcSEcCtD
Rasagiline—MAOB—Metabolism—TAZ—dilated cardiomyopathy	0.00127	0.00421	CbGpPWpGaD
Rasagiline—Asthenia—Lisinopril—dilated cardiomyopathy	0.00125	0.0018	CcSEcCtD
Rasagiline—BCL2—Apoptosis—TNF—dilated cardiomyopathy	0.00125	0.00414	CbGpPWpGaD
Rasagiline—Pruritus—Lisinopril—dilated cardiomyopathy	0.00124	0.00177	CcSEcCtD
Rasagiline—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.0012	0.00172	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.00118	0.00392	CbGpPWpGaD
Rasagiline—Dizziness—Lisinopril—dilated cardiomyopathy	0.00116	0.00166	CcSEcCtD
Rasagiline—MAOB—Metabolism—SDHA—dilated cardiomyopathy	0.00115	0.00381	CbGpPWpGaD
Rasagiline—CYP1A2—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.00114	0.00376	CbGpPWpGaD
Rasagiline—Vomiting—Lisinopril—dilated cardiomyopathy	0.00111	0.00159	CcSEcCtD
Rasagiline—Rash—Lisinopril—dilated cardiomyopathy	0.0011	0.00158	CcSEcCtD
Rasagiline—Dermatitis—Lisinopril—dilated cardiomyopathy	0.0011	0.00158	CcSEcCtD
Rasagiline—Headache—Lisinopril—dilated cardiomyopathy	0.0011	0.00157	CcSEcCtD
Rasagiline—Nausea—Lisinopril—dilated cardiomyopathy	0.00104	0.00149	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—RAF1—dilated cardiomyopathy	0.000999	0.0033	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000995	0.00329	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—EGFR—dilated cardiomyopathy	0.000875	0.00289	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	0.000824	0.00272	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TNF—dilated cardiomyopathy	0.000768	0.00254	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.00074	0.00245	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000704	0.00233	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—EGFR—dilated cardiomyopathy	0.000685	0.00227	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000682	0.00226	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000662	0.00219	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CD36—dilated cardiomyopathy	0.000658	0.00217	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.00065	0.00215	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—RAC1—dilated cardiomyopathy	0.00062	0.00205	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000508	0.00168	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000508	0.00168	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.000484	0.0016	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000484	0.0016	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ITGB1—dilated cardiomyopathy	0.000449	0.00148	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—RAF1—dilated cardiomyopathy	0.000411	0.00136	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD36—dilated cardiomyopathy	0.000383	0.00127	CbGpPWpGaD
Rasagiline—BCL2—Immune System—RAC1—dilated cardiomyopathy	0.000361	0.00119	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	0.000314	0.00104	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GPX1—dilated cardiomyopathy	0.000313	0.00103	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CD36—dilated cardiomyopathy	0.000305	0.00101	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	0.000295	0.000975	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—EGFR—dilated cardiomyopathy	0.000282	0.000931	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—AGT—dilated cardiomyopathy	0.000274	0.000907	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	0.000267	0.000881	CbGpPWpGaD
Rasagiline—BCL2—Immune System—RAF1—dilated cardiomyopathy	0.000239	0.000791	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EGFR—dilated cardiomyopathy	0.000164	0.000542	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000163	0.000538	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000158	0.000524	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000143	0.000471	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	7.24e-05	0.000239	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	7.05e-05	0.000233	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	6.35e-05	0.00021	CbGpPWpGaD
